Ignite Creation Date:
2024-05-06 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05141188
Status:
UNKNOWN
Last Update Posted:
2021-12-02
First Post:
2021-10-07
Brief Title:
Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Prevalence Of Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
Status:
UNKNOWN
Status Verified Date:
2021-11
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Urinary tract infection is among the most common nosocomial and community acquired infections The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy Resistance to antibiotic treatment in patients with urinary tract infections UTIs is a representative example of the increasing problem of antimicrobial resistance Extended-spectrum β-lactamases ESBLs has emerged as an important mechanism of resistance in Gram-negative bacteria
Detailed Description:
Urinary tract infection is among the most common nosocomial and community acquired infections The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy
Resistance to antibiotic treatment in patients with urinary tract infections UTIs is a representative example of the increasing problem of antimicrobial resistance Extended-spectrum β-lactamases ESBLs has emerged as an important mechanism of resistance in Gram-negative bacteria
Bacterial production of extended-spectrum β-lactamases ESBL significantly reduces the efficacy of the most commonly used beta-lactam antibiotics for the empiric therapy of infections caused by putative Gram-negative
Extended Spectrum Beta-Lactamase ESBL is derived from the mutated beta-lactamase enzyme Beta-lactamase is an enzyme produced by bacteria that acts to inactivate beta-lactam class of antibiotics
Extended Spectrum Beta-Lactamase is most commonly produced by the Enterobacteriaceae group especially Escherichia coli and Klebsiella pneumonia
ESBL-producing bacteria can also be resistant to the antibiotics class of aminoglycoside fluoroquinolone tetracycline chloramphenicol and sulfamethoxazole-trimethoprim
The presence of ESBL-producing bacteria in an infection can result in treatment failure Antibiotic resistance causes a decrease in the effectiveness of treatment increases transmission of infection increases mortality and increases the cost of health care while the discovery of new antibiotics is getting less and less
Resistance to antibiotic treatment in patients with urinary tract infections UTIs is a representative example of the increasing problem of antimicrobial resistance Extended-spectrum β-lactamases ESBLs has emerged as an important mechanism of resistance in Gram-negative bacteria
Bacterial production of extended-spectrum β-lactamases ESBL significantly reduces the efficacy of the most commonly used beta-lactam antibiotics for the empiric therapy of infections caused by putative Gram-negative
Extended Spectrum Beta-Lactamase ESBL is derived from the mutated beta-lactamase enzyme Beta-lactamase is an enzyme produced by bacteria that acts to inactivate beta-lactam class of antibiotics
Extended Spectrum Beta-Lactamase is most commonly produced by the Enterobacteriaceae group especially Escherichia coli and Klebsiella pneumonia
ESBL-producing bacteria can also be resistant to the antibiotics class of aminoglycoside fluoroquinolone tetracycline chloramphenicol and sulfamethoxazole-trimethoprim
The presence of ESBL-producing bacteria in an infection can result in treatment failure Antibiotic resistance causes a decrease in the effectiveness of treatment increases transmission of infection increases mortality and increases the cost of health care while the discovery of new antibiotics is getting less and less
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None